John Hart joins Meridica as chief operating officer, and Jeff Hudson as director of process development
Meridica has announced two key senior appointments to its technical team.
John Hart has joined the Cambridge-based drug delivery technology company as chief operating officer.
He will have responsibility for the continuing development of Meridica's technologies, particularly Xcelovair, its dry powder inhaler, the subject of a recent licensing deal with Pfizer.
Hart joins Meridica from Schering Plough where he held the position of senior director, pharmaceutical development and was involved in that company's programme of inhalation technology developments.
He formerly held a number of other senior positions within the pharmaceutical industry including world-wide director of product development for Rh“ne-Poulenc Rorer.
In addition, Jeff Hudson has joined the Meridica team as director of process development.
Hudson joins Meridica from GSK where he has held numerous positions in the manufacturing and supply organisation over the last twenty-five years, most recently director of network rationalisation.
He will be key to ensuring that Meridica meets its process development deadlines. Ian Smith, Meridica's CEO said "the appointment of John Hart and Jeff Hudson to these key positions reflects the importance we place on achieving and delivering technological excellence, on time, to our current and future licensees. "The appointment of people with the knowledge, experience and reputation of John and Jeff will serve to enhance considerably Meridica's position within the industry".
